AIMS: To evaluate whether CMR-derived RV assessment can facilitate risk stratification among patients undergoing transcatheter mitral valve repair (TMVR). BACKGROUND: In patients undergoing TMVR, only limited data exist regarding the role of RV function. Previous studies assessed the impact of pre-procedural RV dysfunction stating that RV failure may be associated with increased cardiovascular mortality after the procedure. METHODS: Sixty-one patients underwent CMR, echocardiography and right heart catheterization prior TMVR. All-cause mortality and heart failure hospitalizations were assessed during 2-year follow-up. RESULTS: According to RV ejection fraction (RVEF) <46%, 23 patients (38%) had pre-existing RV dysfunction. By measures of RV end-diastolic volume index (RVEDVi), 16 patients (26%) revealed RV dilatation. Nine patients (15%) revealed both. RV dysfunction was associated with increased right and left ventricular volumes as well as reduced left ventricular (LV) ejection fraction (all p<0.05). During follow-up, 15 patients (25%) died and additional 14 patients (23%) were admitted to hospital due to heart failure symptoms. RV dysfunction predicted all-cause mortality even after adjustment for LV function. Similarly, RVEDVi was a predictor of all-cause mortality even after adjustment for LVEDVi. Kaplan-Meier survival analysis unraveled that, among patients presenting with CMR indicative of both, RV dysfunction and dilatation, the majority (78%) experienced an adverse event during follow-up (p<0.001). CONCLUSION: In patients undergoing TMVR, pre-existing RV dysfunction and RV dilatation are associated with reduced survival, in progressive additive fashion. The assessment of RV volumes and function by CMR may aid in risk stratification prior TMVR in these high-risk patients.
AIMS: To evaluate whether CMR-derived RV assessment can facilitate risk stratification among patients undergoing transcatheter mitral valve repair (TMVR). BACKGROUND: In patients undergoing TMVR, only limited data exist regarding the role of RV function. Previous studies assessed the impact of pre-procedural RV dysfunction stating that RV failure may be associated with increased cardiovascular mortality after the procedure. METHODS: Sixty-one patients underwent CMR, echocardiography and right heart catheterization prior TMVR. All-cause mortality and heart failure hospitalizations were assessed during 2-year follow-up. RESULTS: According to RV ejection fraction (RVEF) <46%, 23 patients (38%) had pre-existing RV dysfunction. By measures of RV end-diastolic volume index (RVEDVi), 16 patients (26%) revealed RV dilatation. Nine patients (15%) revealed both. RV dysfunction was associated with increased right and left ventricular volumes as well as reduced left ventricular (LV) ejection fraction (all p<0.05). During follow-up, 15 patients (25%) died and additional 14 patients (23%) were admitted to hospital due to heart failure symptoms. RV dysfunction predicted all-cause mortality even after adjustment for LV function. Similarly, RVEDVi was a predictor of all-cause mortality even after adjustment for LVEDVi. Kaplan-Meier survival analysis unraveled that, among patients presenting with CMR indicative of both, RV dysfunction and dilatation, the majority (78%) experienced an adverse event during follow-up (p<0.001). CONCLUSION: In patients undergoing TMVR, pre-existing RV dysfunction and RV dilatation are associated with reduced survival, in progressive additive fashion. The assessment of RV volumes and function by CMR may aid in risk stratification prior TMVR in these high-risk patients.
Authors: Marvin A Konstam; Michael S Kiernan; Daniel Bernstein; Biykem Bozkurt; Miriam Jacob; Navin K Kapur; Robb D Kociol; Eldrin F Lewis; Mandeep R Mehra; Francis D Pagani; Amish N Raval; Carey Ward Journal: Circulation Date: 2018-04-12 Impact factor: 29.690
Authors: Alistair C Lindsay; Katie Harron; Richard J Jabbour; Ritesh Kanyal; Thomas M Snow; Paramvir Sawhney; Francisco Alpendurada; Michael Roughton; Dudley J Pennell; Alison Duncan; Carlo Di Mario; Simon W Davies; Raad H Mohiaddin; Neil E Moat Journal: Circ Cardiovasc Interv Date: 2016-07 Impact factor: 6.546
Authors: Thierry Le Tourneau; Guillaume Deswarte; Nicolas Lamblin; Claude Foucher-Hossein; Georges Fayad; Marjorie Richardson; Anne-Sophie Polge; Claire Vannesson; Yan Topilsky; Francis Juthier; Jean-Noel Trochu; Maurice Enriquez-Sarano; Christophe Bauters Journal: Circulation Date: 2013-03-13 Impact factor: 29.690
Authors: Thomas M Gorter; Joost P van Melle; Michiel Rienstra; Barry A Borlaug; Yoran M Hummel; Isabelle C van Gelder; Elke S Hoendermis; Adriaan A Voors; Dirk J van Veldhuisen; Carolyn S P Lam Journal: J Card Fail Date: 2017-11-29 Impact factor: 5.712
Authors: Paolo Manca; Vincenzo Nuzzi; Antonio Cannatà; Matteo Castrichini; Daniel I Bromage; Antonio De Luca; Davide Stolfo; Uwe Schulz; Marco Merlo; Gianfranco Sinagra Journal: Heart Fail Rev Date: 2022-03-22 Impact factor: 4.654